Skip to main content

Table 1 TAR–adjusted CF-AE rates in LL3, LL1, and a pooled analysis of 3865 patients

From: Cardiac safety of afatinib: a review of data from clinical trials

LL3 Afatinib (40 mg/day) n = 229 Chemotherapy n = 111
 TAR (mo) 11.5 3.7
 TAR-adjusted CF-AE rate (events/100 patient-years) 2.28 2.92
 HR (95 % CI) 1.18 (0.12, 11.39; p = 0.8870)
LL1 Afatinib (50 mg/day) n = 390 Placebo n = 195
 TAR (mo) 5.1 2.8
 TAR-adjusted CF-AE rate (events/100 patient-years) 2.40 2.23
 HR (95 % CI) 1.32 (0.14, 12.50; p = 0.8086)
Pooled Afatinib n = 3865  
 TAR (mo) 5.7  
 TAR-adjusted CF-AE rate (events/100 patient-years) 2.88  
  1. TAR time at risk, CF-AE cardiac failure adverse event, LL3 LUX-Lung 3, LL1 LUX-Lung 1, HR hazard ratio, CI confidence interval